{"name":"Nektar Therapeutics","slug":"nektar","ticker":"NKTR","exchange":"NASDAQ","domain":"nektar.com","description":"Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough.","hq":"San Francisco, CA","founded":0,"employees":"63","ceo":"Howard W. Robin","sector":"Immunology / Oncology","stockPrice":73.22,"stockChange":-2.73,"stockChangePercent":-3.59,"marketCap":"$2.5B","metrics":{"revenue":307711000,"revenueGrowth":3.8,"grossMargin":100,"rdSpend":117330000,"netIncome":-164076000,"cash":568604032,"dividendYield":0,"peRatio":-5.8,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"bempegaldesleukin patent cliff ($1.5B at risk)","drug":"bempegaldesleukin","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Nektar Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Nektar reported a net loss of $1.1 billion for the full year 2023, compared to a net loss of $1.3 billion in 2022.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Nektar Therapeutics Announces Collaboration with Merck to Develop and Commercialize NKTR-214","summary":"Nektar and Merck entered into a collaboration to develop and commercialize NKTR-214, a cancer immunotherapy.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"trial","headline":"Nektar Therapeutics Announces Positive Topline Results from Phase 3 Trial of bempegaldesleukin","summary":"Nektar announced positive topline results from a Phase 3 trial of bempegaldesleukin in patients with metastatic urothelial carcinoma.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxNQ3BKVFE4NzM1eklMR2dtT0ZEVGVwekE0VzFQbkx6aUNSZkM4Yzl5eEtmdjBSZHNsQVpIcW5iODRjdzJVWDFFcmViZWZ5S1V1bWhLSEdtdDd6YVpEX2NMWW1SNjJVbzItWk1nWk9MUnNQVU9xd3d6dFVxZE9BVnB0RFVnVmwzc2I4UmNINWJma3JTckFUNGZuaFNyZVF2Mzk5NHF0QU1qZWVwTTZ6WEhhOU5acDVHR3dNcHdjaUZ4aWdTaVVxdW5IM3pfY3oycVQ2dVNTcnJ1WW82VkFYSmdOQ3AxczgzY19N0gHuAUFVX3lxTE9weEhRczU4bEdlTERmX2JGY3VwRC1aZzRxOW5jZEhNUjVTeEpHaURzSktoUDhxdGhSZkpEWHBXZlZjelVYUWdVUDFOS1VfOXk5Qy1lT1RiNWxKUFNwQ2FZME83TXhBTkM0N3hIa0sycFZMQXJ2S2E5aXEwc01QRnk3bWNyR2Zpa3dXak5sVDBOWkNweDhjLXVjRUM3aGM0NWdleG81QWRjckJ2RGdya2I2QnBiTGcwelZwcFc3d2pzd01BSXVkczJhLXZiZG95VFQ3OXNSRU5hX1BCdG1lTFdGS2hBV0FIMWE5WGY0a0E?oc=5","date":"2026-04-02","type":"pipeline","source":"simplywall.st","summary":"Assessing Nektar Therapeutics (NKTR) Valuation After A Sharp Multi‑Month Share Price Run - simplywall.st","headline":"Assessing Nektar Therapeutics (NKTR) Valuation After A Sharp Multi‑Month Share Price Run","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwJBVV95cUxNZXFZYjhvMFZkbDEyZmZUR2I0WmlRRUVNbHVfY1FtUnV0NDg0Zng3dW54bFBXQk1PTFN6UjUtUEcxbzRWdkxBSjhsTHkyb1EwUVp5X2xOLWlUeFpVMjBtTUJQYWxFWEFfZ0NYeGZwTHpuZXMxUURIU0ZBSzBZVERfaWItY2N4ZDdiZ2Nac3ljdkNwVFc2ZXFmODNHRHJrWTViTXRPdzQ3NkgtTi1CSDA3WlRtX3Y0UV8tbkFxbzR3N0EzRVZLcXIxZ0tDaG1uVkhibjJmYnFmNEZzUDVEaGdDaVVsUWFUN2cyUnlna1FDYVJMcF9CT0Y1NzVPQnUxOWtNeVdnVVpTVlNCOG55WklQclhlZVdWU0k1NWwzVXRUOGlNWXBfcDc1Sk1KS0N1bWVzbEFGTUE4WVFvT3JaeUs0WUNfWQ?oc=5","date":"2026-03-31","type":"pipeline","source":"globenewswire.com","summary":"NKTR Stockholders Have Rights – If You Lost Money Investing - globenewswire.com","headline":"NKTR Stockholders Have Rights – If You Lost Money Investing","sentiment":"neutral"},{"date":"2026-03-13","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxQOFJ4MFhtZFFKbTlfdzRIS2E2NDByN0Z5emNmX0VJeTRBdHJLN2ZrS1J6RllkZHR0WUtzYmRnNXh4SUhfRUtqTkM1NHJaNU9JM1FqaVJsMGowcEplZ0ZDUEotVXgxT2kteVpFSXNOSGhyaUh3M3k2TTdBWml1QjhraUZwQmRkVmJMQXc4cGJEVkhWb3ZIZ2RtbThjVFJEalZPblNKV3FvbnR3a0JUVWdYUkJqb3cydW9FMG5tblNuYmxvWmdqcFZJd2lQM1BQS1pobHVqaGJDM0tLdmJqeEk4RU1xY3M?oc=5","date":"2026-03-06","type":"pipeline","source":"Business Wire","summary":"Investor Notice: Robbins LLP Informs Investors of the Nektar Therapeutics Class Action Lawsuit - Business Wire","headline":"Investor Notice: Robbins LLP Informs Investors of the Nektar Therapeutics Class Action Lawsuit","sentiment":"neutral"},{"date":"2026-02-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-12","type":"pipeline","source":"simplywall.st","summary":"Nektar Therapeutics' (NASDAQ:NKTR) Shares Climb 81% But Its Business Is Yet to Catch Up - simplywall.st","headline":"Nektar Therapeutics' (NASDAQ:NKTR) Shares Climb 81% But Its Business Is Yet to Catch Up","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQVFZpbW51NTNPOUliZ0U2YkFJRDJ5Nm4zMUlmdDkzRm14NEdFLXJUbDJHMzdOckFsNHQxVGp6bUMxVUhrRV9DNU96UllNZlhhZXhoN0JFOW16c3B3YVZRUEx2X05YakVQalNIaUw3YWkzWTEwYjRqeG9Sb1hyaThFeFRRdmhWZUtKaVdYVFRNVHZBdjloOWlId2x1TGJyM1FrZjg1NVFtc181RnEwMUc0?oc=5","date":"2026-02-10","type":"pipeline","source":"PR Newswire","summary":"Nektar Therapeutics Announces Proposed Public Offering - PR Newswire","headline":"Nektar Therapeutics Announces Proposed Public Offering","sentiment":"neutral"},{"date":"2026-02-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQaHNyZWtjVnNRZzctdWE4VDVqNFRlR3oxSE05eGF0ZTB5aUFOTjhNYXc5VDJsUU9ib3NVZ2ozREpDWjhkUnpKZmhGQklhNXNGaUpUN0dwclFIY1kxS1l6bHRaaDh2Q3Q3ZmNtc2dJNnJoT1pIeGNGcVZ5U3BfMmV1VnBxeldPTnF0RWFQVXZuQQ?oc=5","date":"2026-01-08","type":"pipeline","source":"Yahoo Finance","summary":"Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics - Yahoo Finance","headline":"Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceutic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQX2xLdGNxbThTZUotMzM0V2oweEZkV3cyeTgwdGJVVDFuUlBhVWUxa29VMHFMamx1dTlkZEg3MFdmQ3NlZ19UQTRnOVBORzl3SVNwOS1JcG05Rmd4UTd0Sy02MHlNOGFKN2NRbFZVUF9UcnpMVVdUMmR1VzBVcEN6elJhbkJXeFB3R0R4ZXdqN3h1eXZqRUow?oc=5","date":"2026-01-05","type":"pipeline","source":"The Motley Fool","summary":"Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead - The Motley Fool","headline":"Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQX0QybHdMbEI5VGNYZ1dnaERnUFdpZGpWWERhZlFzS0VsSURTb1NQekxzczc5cjJsc1JZcnc3THp4SWtyQTZVcFVHb1lIUWt1cVR1dzMycWR2aEtPS3BfTzB2R3ZGYURWR0tWNTVuUjF2cnE1Y3pxMGphd19VWTBDeGlQeFpXMkNkVHJ4ejJiLV9HVUthTTZJRGlnQWVuU1gyRkxWLWJPOU9PSkIta2tNdllrVGhVZmY3eTd3VWRGRGJYQQ?oc=5","date":"2025-11-07","type":"earnings","source":"TradingView","summary":"Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y - TradingView","headline":"Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE92alBNTkxpbEZKTnJfYkJyVF9sWVNsQzRKZVFHYnNKYmttV2hJNktrMlBaeHZXR2ZDQmROYVlaSXNBQXMwM0ZaeUhKa1NMblNNcE1GeV9vLXVlaVVsM3VkeEhaUHJPcWFzNnQtS2x2WVpyWHhaWk90dmlBUlowUXM?oc=5","date":"2025-10-20","type":"deal","source":"BioSpace","summary":"Rumors of Eli Lilly Buyout Send Nektar’s Shares Spiking - BioSpace","headline":"Rumors of Eli Lilly Buyout Send Nektar’s Shares Spiking","sentiment":"neutral"}],"patents":[{"drugName":"bempegaldesleukin","drugSlug":"bempegaldesleukin","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1500000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":5,"keyCompetitors":["Bristol-Myers Squibb","Merck & Co.","Gilead Sciences"],"therapeuticFocus":["Immunology","Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":307711000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":307711000,"period":"2017-12-31"},{"value":95466000,"period":"2017-12-31"},{"value":152928000,"period":"2017-09-30"},{"value":34589000,"period":"2017-06-30"},{"value":24728000,"period":"2017-03-31"}],"grossProfit":55232000,"grossProfitHistory":[{"period":"2025-12-31","value":55232000},{"period":"2024-12-31","value":67741000},{"period":"2023-12-31","value":56354000},{"period":"2022-12-31","value":70420000}],"rdSpend":117330000,"rdSpendHistory":[{"period":"2025-12-31","value":117330000},{"period":"2024-12-31","value":120908000},{"period":"2023-12-31","value":114162000},{"period":"2022-12-31","value":218323000}],"sgaSpend":68673000,"operatingIncome":-130771000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-130771000},{"period":"2024-12-31","value":-129918000},{"period":"2023-12-31","value":-135225000},{"period":"2022-12-31","value":-240236000}],"netIncome":-164076000,"netIncomeHistory":[{"period":"2025-12-31","value":-164076000},{"period":"2024-12-31","value":-118961000},{"period":"2023-12-31","value":-276056000},{"period":"2022-12-31","value":-368198000}],"eps":-9.73,"epsHistory":[{"period":"2025-12-31","value":-9.73},{"period":"2024-12-31","value":-8.7},{"period":"2023-12-31","value":-21.75},{"period":"2022-12-31","value":-29.55}],"cash":15116000,"cashHistory":[{"period":"2025-12-31","value":15116000},{"period":"2024-12-31","value":44252000},{"period":"2023-12-31","value":35277000},{"period":"2022-12-31","value":88227000}],"totalAssets":280406000,"totalLiabilities":190574000,"totalDebt":85751000,"equity":89832000,"operatingCashflow":-208511000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-208511000},{"period":"2024-12-31","value":-175709000},{"period":"2023-12-31","value":-192606000},{"period":"2022-12-31","value":-304007000}],"capex":-171000,"capexHistory":[{"period":"2025-12-31","value":-171000},{"period":"2024-12-31","value":-1468000},{"period":"2023-12-31","value":-865000},{"period":"2022-12-31","value":-5676000}],"freeCashflow":-208682000,"dividendsPaid":null,"buybacks":0,"employees":63,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":null,"ebit":-24933000,"ebitda":-24743000,"period":"2025-12-31","revenue":21807000,"epsBasic":-1.78,"netIncome":-36079000,"rdExpense":29712000,"epsDiluted":-1.78,"grossProfit":21807000,"operatingIncome":-19090000},{"sga":null,"ebit":-28974000,"ebitda":-28778000,"period":"2025-09-30","revenue":11790000,"epsBasic":-1.87,"netIncome":-35522000,"rdExpense":27252000,"epsDiluted":-1.87,"grossProfit":11790000,"operatingIncome":-31532000},{"sga":null,"ebit":-34001000,"ebitda":-33787000,"period":"2025-06-30","revenue":11175000,"epsBasic":-2.95,"netIncome":-41593000,"rdExpense":29886000,"epsDiluted":-2.95,"grossProfit":11175000,"operatingIncome":-35783000},{"sga":null,"ebit":-41395000,"ebitda":-40969000,"period":"2025-03-31","revenue":10460000,"epsBasic":-3.6,"netIncome":-50882000,"rdExpense":30480000,"epsDiluted":-3.6,"grossProfit":10460000,"operatingIncome":-44366000},{"sga":null,"ebit":17155000,"ebitda":17487000,"period":"2024-12-31","revenue":29175000,"epsBasic":0.45,"netIncome":7261000,"rdExpense":28745000,"epsDiluted":0.45,"grossProfit":21198000,"operatingIncome":-24682000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":73.22,"previousClose":75.95,"fiftyTwoWeekHigh":109,"fiftyTwoWeekLow":7.99,"fiftyTwoWeekRange":"7.99 - 109.0","fiftyDayAverage":78.77,"twoHundredDayAverage":56.05,"beta":1.25,"enterpriseValue":1453532160,"forwardPE":-5.8,"priceToBook":3.14,"priceToSales":44.47,"enterpriseToRevenue":26.13,"enterpriseToEbitda":-11.74,"pegRatio":0,"ebitda":-123806496,"ebitdaMargin":-222.5,"freeCashflow":0,"operatingCashflow":0,"totalDebt":143432000,"debtToEquity":24.9,"currentRatio":10.21,"returnOnAssets":-15.3,"returnOnEquity":-53.6,"analystRating":"1.3 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":8,"targetMeanPrice":153.25,"targetHighPrice":192,"targetLowPrice":80,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.4,"institutionHeldPercent":58.2,"sharesOutstanding":33786032,"floatShares":23203667,"sharesShort":4102558,"shortRatio":3.37,"shortPercentOfFloat":12.1,"epsTrailing":-7.93,"epsForward":-12.56,"revenuePerShare":2.85,"bookValue":23.3,"officers":[{"age":72,"name":"Mr. Howard W. Robin","title":"CEO, President & Director"},{"age":59,"name":"Ms. Sandra A. Gardiner","title":"Interim Chief Financial Officer"},{"age":50,"name":"Dr. Jonathan  Zalevsky Ph.D.","title":"Senior VP and Chief Research & Development Officer"},{"age":null,"name":"Mr. Jason  Barnard","title":"Chief Accounting Officer"},{"age":null,"name":"Ms. Elizabeth  Zhang","title":"VP of Legal, Corporate Counsel & Secretary"},{"age":null,"name":"Mr. Robert  Bacci","title":"Chief People Officer and Head of Quality & Facilities"},{"age":null,"name":"Ms. Jennifer  Ruddock","title":"Chief Business Officer"},{"age":59,"name":"Dr. Mary  Tagliaferri L.Ac., M.D.","title":"Chief Medical Officer"}],"industry":"Biotechnology","irWebsite":"http://ir.nektar.com/","website":"https://www.nektar.com","phone":"415 482 5300"}}